AVISCERA BIOSCIENCE
| CD146 (Soluble) (Human) ELISA Kit | |
| CD146 is a biomarker for Cardiovascular Diseases, Diabetes and Obesity research | |
|
|
CD146 Deletion in the Nervous System Impairs Appetite, Locomotor Activity and Spatial Learning in Mice |
|
| Cell adhesion molecules (CAMs) are crucial effectors for the development and maintenance of the nervous system. Mutations in human CAM genes are linked to brain disorders and psychological diseases, and CAM knockout mice always exhibit similar behavioral abnormalities. CD146 is a CAM of the immunoglobulin superfamily that interacts with Neurite Outgrowth Factor and involved in neurite extension in vitro. However, little is known about its in vivo function in the nervous system. In this study, we used a murine CD146 nervous system knockout (CD146(ns-ko)) model. We found that the brains of some CD146(ns-ko) mice were malformed with small olfactory bulbs. CD146(ns-ko) mice exhibited lower body weights and smaller food intake when compared with wild type littermates. Importantly, behavior tests revealed that CD146(ns-ko) mice exhibited significant decreased locomotor activity and impaired capacity for spatial learning and memory. Our results demonstrate that CD146 is important for mammalian nervous system development and proper behavior patterns. | |
| Tu T et al. PLoS One. 2013 Sep 10;8(9):e74124. doi: 10.1371/journal.pone.0074124. | |
The relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic patients as evidenced by measurement of carotid intima-media thickness and soluble CD146 levels: a cross sectional study |
|
| BACKGROUND: Detection of early vascular changes prior to clinical manifestations of atherosclerosis, such as increased arterial carotid intima-media thickness (CIMT) and impaired endothelial function is of paramount importance for early identification of subjects at increased risk of accelerated atherosclerosis. The present study was designed to evaluate the relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic patients based on measurements of CIMT and soluble CD146 (sCD146) levels. METHODS: Thirty-seven patients with type 1 diabetes, 14 males (37.8%) and 23 females (62.2%), of mean (SD) age 26.2 (4.1) years admitted to the outpatient diabetes clinic at Okmeydani Training and Research Hospital, Istanbul, between January 2008 and December 2012, and 37 healthy controls, 16 males (43.2%) and 21 females (56.8%), of mean (SD) age 25.8 (3.1) years, selected from relatives of patients, were included. Anthropometric measures; fasting plasma glucose; and serum HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride and creatinine concentrations were compared, as were CIMT and serum sCD146. RESULTS: Mean (SD) sCD146 concentrations were significantly higher in patients than in controls (314.6 (141.9) ng/ml vs. 207.8 (34.5) ng/ml, p = 0.001), but mean (SD) CIMT did not differ (0.5 (0.1) mm vs. 0.4 (0.1) mm). ROC curves for sCD146 significantly differed in differentiating type 1 diabetics from healthy controls (p = 0.0047) with a significantly higher percentage of patients than controls having sCD146 concentrations >260 ng/ml (21/37 (56.8%) vs. 2/37 (5.4%), p = 0.00011). CONCLUSION: Our findings emphasize that sCD146 levels may be a more sensitive marker than CIMT for earlier identification of type 1 diabetic patients at high risk for atherosclerosis. |
|
| Dogansen SC et al. Cardiovasc Diabetol. 2013 Oct 18;12(1):153. [Epub ahead of print] | |
Soluble CD146 in cerebrospinal fluid of active multiple sclerosis |
|
| The soluble form of CD146 has been reported to be present in various inflammatory diseases and displays pro-inflammatory properties. However, little is known about sCD146 in multiple sclerosis (MS). Here we show that sCD146 is significantly elevated in the cerebrospinal fluid of patients with active MS compared with that of inactive MS or patients with non-demyelinating diseases. Moreover, abnormally increased sCD146 in the CSF of active MS patients correlated with albumin quotient, MBP antibody and MOG antibody from both CSF and sera. Importantly, the level of CSF sCD146 is correlated with levels of inflammatory factors, such as TNFα, IFNγ, IL-2, and IL-17A in the CSF. We also found that CSF sCD146 might originate from membrane-bound CD146 on inflamed blood-brain barrier (BBB) endothelial cells. In addition, sCD146 promotes leukocyte transmigration in vitro, at least in part by stimulating the expression of ICAM-1 and VCAM-1 on endothelial cells. Our findings suggest that CSF levels of sCD146 may provide a potential marker for monitoring disease activity in MS patients. | |
| Duan H, et al. Neuroscience. 2013 Apr 3;235:16-26. doi: 10.1016/j.neuroscience.2013.01.020. Epub 2013 Jan 16. | |
 |
|
 |
CD146 (Soluble) (Human) ELISA Kit Code No.: SK00628-01 Size: 96 T Price: Standard range:31.25-2000 pg/ml Sensitivity: 10 pg/ml Sample type: plasma, serum Intra-CV: 4-6% Inter-CV: 8-10% Data Sheet: PDF |
 |
Human
Soluble CD146 Recombinant Code No.: 00628-02-10 Size: 100 ug Price: $160.00 USD Protein ID:NP_006491.2 Gene ID: NM_006500.0 MW:80-90 KD (Glycosylated) Tag: His Tag on C-Terminus Expressed: Human HEK293 cells Purity: 98% Data Sheet: PDF |
| Name | Code |
Size |
Price ($) |
| CD146 (Soluble) (Human) ELISA Kit | 96 T |
||
| Cd146 (Soluble) (Human), Standard | 628-01-02 |
2 ng |
80.00 |
| Anti CD146 (Human) IgG HRP | 628-01-03 |
96 xrns |
160.00 |
| Soluble CD146 (Human) (HEK293 derived) Rec | 10 ug |
160.00 |
|
| Soluble CD146 (Human) (HEK293 derived) Rec | 50 ug |
340.00 |
|
| Anti Soluble CD146 (Human)Antibody | A00628-03-50 |
50 ug |
360.00 |